• Published On : Apr-2015 |
  • Pages : 92 Pages |
  • Format :

Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter’s Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market drivers

     4.2.1 Rising aging population

     4.2.2 Increasing incidence of eye disorders

     4.2.3 Growing government initiatives to reduce eye disorders

     4.2.4 Increasing R&D investments in drug discovery and development

4.3 Impact Analysis of Market Drivers

4.4 Market restraints

     4.4.1 Lack of awareness about eye disorders

     4.4.2 Poor primary healthcare infrastructure and lack of health insurance in developing countries

4.5 Impact analysis of market restraints

4.6 Market Trends

     4.6.1 Increasing usage of anti-TNF-alpha inhibitor therapy

     4.6.2 Rising incidence of drug-induced uveitis

4.7 Market Opportunities

     4.7.1 Use of electronic medical records

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Type

6.1 Anterior uveitis

6.2 Posterior uveitis

6.3 Intermediate uveitis

6.4 Panuveitis

Chapter 7 Market Size and Forecast by Treatment

7.1 Anti-inflammatory medications

7.2 Antibiotic or antiviral medications

7.3 Immunosuppressive medications

Chapter 8 Market Size and Forecast by Geography

8.1 North America

     8.1.1 Scenario in the U.S.

8.2 Europe

     8.2.1 Scenario in Germany

     8.2.2 Scenario in France

     8.2.3 Scenario in the U.K

8.3 Asia

     8.3.1 Scenario in Japan

     8.3.2 Scenario in China

     8.3.3 Scenario in India

Chapter 9 Pipeline Drugs for Uveitis Treatment

9.1 Drugs under development for Uveitis Treatment

Chapter 10 Competitive Scenario

10.1 Competitive Benchmarking

Chapter 11 Company Profiles

11.1 Regeneron Pharmaceuticals, Inc.

     11.1.1 Company overview

     11.1.2 Products and services

     11.1.3 Financial performance

     11.1.4 Key developments

11.2 pSivida Corp.

     11.2.1 Company overview

     11.2.2 Products and services

     11.2.3 Financial performance

     11.2.4 Key developments

11.3 XOMA Corporation

     11.3.1 Company overview

     11.3.2 Products and services

     11.3.3 Financial performance

     11.3.4 Key developments

11.4 Alcon, Inc.

     11.4.1 Company overview

     11.4.2 Products and services

     11.4.3 Financial performance

     11.4.4 Key developments

11.5 Allergan, Inc.

     11.5.1 Company overview

     11.5.2 Products and services

     11.5.3 Financial performance

     11.5.4 Key developments

11.6 AbbVie Inc.

     11.6.1 Company overview

     11.6.2 Products and segments

     11.6.3 Financial performance

     11.6.4 Key developments

11.7 Santen Pharmaceutical Co., Ltd.

     11.7.1 Company overview

     11.7.2 Products and segments

     11.7.3 Financial performance

     11.7.4 Key developments

11.8 Enzo Biochem Inc.

     11.8.1 Company overview

     11.8.2 Products and segments

     11.8.3 Financial performance

     11.8.4 Key developments

11.9 OphthaliX Inc.

     11.9.1 Company overview

     11.9.2 Products and segments

     11.9.3 Financial performance

     11.9.4 Key developments

11.10 Bausch & Lomb Incorporated

     11.10.1 Company overview

     11.10.2 Products and segments

     11.10.3 Financial performance

     11.10.4 Key developments

11.11 Artielle ImmunoTherapeutics, Inc.

     11.11.1 Company overview

     11.11.2 Products and segments

     11.11.3 Financial performance

     11.11.4 Key developments

11.12 Eyegate Pharmaceuticals, Inc.

     11.12.1 Company overview

     11.12.2 Products and segments

     11.12.3 Financial performance

     11.12.4 Key developments


List of Tables

TABLE 1 Market snapshot: Uveitis treatment market, 2014 and 2020

TABLE 2 Drivers for uveitis treatment market: Impact analysis

TABLE 3 Out-of-pocket expenditure of developing and developed countries in 2013

TABLE 4 Restraints for uveitis treatment market: Impact analysis

TABLE 5 Global uveitis treatment market size, by region, 2010 – 2013 (USD million)

TABLE 6 Global uveitis treatment market size, by region, 2014 – 2020 (USD million)

TABLE 7 Global uveitis treatment market size, by type, 2010 – 2013 (USD million)

TABLE 8 Global uveitis treatment market size, by type, 2014 – 2020 (USD million)

TABLE 9 Global uveitis treatment market size, by treatment, 2010 – 2013 (USD million)

TABLE 10 Global uveitis treatment market size, by treatment, 2014 – 2020 (USD million)

TABLE 11 Global anterior uveitis treatment market size, by region, 2010 – 2013 (USD million)

TABLE 12 Global anterior uveitis treatment market size, by region, 2014 – 2020 (USD million)

TABLE 13 Global posterior uveitis treatment market size, by region, 2010 – 2013 (USD million)

TABLE 14 Global posterior uveitis treatment market size, by region, 2014 – 2020 (USD million)

TABLE 15 Global intermediate uveitis treatment market size, by region, 2010 – 2013 (USD million)

TABLE 16 Global intermediate uveitis treatment market size, by region, 2014 – 2020 (USD million)

TABLE 17 Global panuveitis treatment market size, by region, 2010 – 2013 (USD million)

TABLE 18 Global panuveitis treatment market size, by region, 2014 – 2020 (USD million)

TABLE 19 Global anti-inflammatory medications market size, by region, 2010 – 2013 (USD million)

TABLE 20 Global anti-inflammatory medications market size, by region, 2014 – 2020 (USD million)

TABLE 21 Global antibiotic/antiviral medications market size, by region, 2010 – 2013 (USD million)

TABLE 22 Global antibiotic/antiviral medications market size, by region, 2014 – 2020 (USD million)

TABLE 23 Global immunosuppressive medications market size, by region, 2010 – 2013 (USD million)

TABLE 24 Global immunosuppressive medications market size, by region, 2014 – 2020 (USD million)

TABLE 25 The North American uveitis treatment market size, by country, 2010 – 2013 (USD million)

TABLE 26 The North American uveitis treatment market size, by country, 2014 – 2020 (USD million)

TABLE 27 The European uveitis treatment market size, by country, 2010 – 2013 (USD million)

TABLE 28 The European uveitis treatment market size, by country, 2014 – 2020 (USD million)

TABLE 29 The Asian uveitis treatment market size, by country, 2010 – 2013 (USD million)

TABLE 30 The Asian uveitis treatment market size, by country, 2014 – 2020 (USD million)

TABLE 31 Major pipeline drugs for uveitis treatment

TABLE 32 Product category of Regeneron Pharmaceuticals, Inc.

TABLE 33 Product category of pSivida Corp.

TABLE 34 Product category of XOMA Corporation

TABLE 35 Major product categories of Alcon, Inc.

TABLE 36 Major product categories of Allergan, Inc.

TABLE 37 Product segment of AbbVie Inc.

TABLE 38 Major product categories of Santen Pharaceutical Co., Ltd. 

TABLE 39 Product segments of Enzo Biochem Inc.

TABLE 40 Product category of OphthaliX Inc.

TABLE 41 Major product categories of Bausch & Lomb Incorporated.

TABLE 42 Product category of Artielle ImmunoTherapeutics, Inc.

TABLE 43 Product category of Eyegate Pharmaceuticals, Inc.


List of Figures 

FIG. 1 Uveitis treatment market: Porter’s five forces analysis

FIG. 2 Major types of uveitis treatment

FIG. 3 Aging population in major countries, 2000 – 2050 (% share in total population)

FIG. 4 Global uveitis treatment market share, by region, by value, 2013

FIG. 5 Global uveitis treatment market share, by type, by value, 2013

FIG. 6 Global uveitis treatment market share, by treatment, by value, 2013

FIG. 7 Global anterior uveitis treatment market share, by region, by value, 2013

FIG. 8 Global posterior uveitis treatment market share, by region, by value, 2013

FIG. 9 Global intermediate uveitis treatment market share, by region, by value, 2013

FIG. 10 Global panuveitis treatment market share, by region, by value, 2013

FIG. 11 Global anti-inflammatory medications market share, by region, by value, 2013

FIG. 12 Global antibiotic or antiviral medications market share, by region, by value, 2013

FIG. 13 Global immunosuppressive medications market share, by region, by value, 2013

FIG. 14 The North American uveitis treatment market share, by country, by value, 2013

FIG. 15 The European uveitis treatment market share, by country, by value, 2013

FIG. 16 The Asian uveitis treatment market share, by country, by value, 2013

FIG. 17 Research and development expenditures of major players in the market

FIG. 18 Revenue and net income of Regeneron Pharmaceuticals, Inc., 2012 – 2014 (USD million)

FIG. 19 Total revenues and net income of pSivida Corp., 2012 – 2014 (USD million)

FIG. 20 Total revenue and net income of XOMA Corporation, 2011 – 2013 (USD million)

FIG. 21 Net sales and operating income of Alcon, Inc., 2011 – 2013 (USD million)

FIG. 22 Total revenues and operating income of Allergan, Inc., 2012 – 2014 (USD million)

FIG. 23 Net sales and net earnings of AbbVie Inc., 2012 – 2014 (USD million)

FIG. 24 Net sales and net income of Santen Pharmaceutical Co., Ltd., 2012 – 2014 (USD million)

FIG. 25 Revenues and net loss of Enzo Biochem Inc., 2012 – 2014 (USD million)

FIG. 26 Revenues and operating income of Valeant Pharmaceuticals International, Inc., 2012 – 2014 (USD million)